<prompt> All of the following are true about rituximab except?Chimeric monoclonal antibody against CD-20 B cell antigenMost common side effect is infusion reactionFirst FDA drug approved for resistant lymphomasDose independent pharmacokinetics  <response>: Ans. d. Dose independent pharmacokinetics Ref: Harrison 19e p2147,18e p2749; Katzung 12e p646; htt: orgdocumentsfile1442_2pdfPharmacokinetics of rituximab monoclonal antibodies is dose dependent.The rate of uptake and elimination of antibodies by target-mediated pathways is a function of dose and the expression level of the target, as well as a function of the kinetics of receptor internalization and intracellular catabolism http: is a murine-human monoclonal IgG1 human Fc that binds to the CD20 molecule on normal and malignant B lymphocytesQMechanism of Action:The mechanism of action includes complement-mediated lysis, antibody-dependent cellular cytotoxicity, and induction of apoptosis in the malignant lymphoma cellsQ.Indications:Approved for relapsed or refractory low-grade or follicular B cell non-Hodgkins lymphomaQ.Approved for the treatment of refractory RA in combination with methotrexate and has been shown to be more effective for patients with seropositive than seronegative diseaseQ.Side-effects:Associated with mild-to- moderate infusion reactions as well as an increased risk of infectionQ.Notably, there have been isolated reports of a potentially lethal brain disorder, progressive multifocal leukoencephalopathy PML, in association with rituximab therapy.It has been also shown to cause Tuberculosis.Pharmacokinetics:The rate of uptake and elimination of antibodies by target-mediated pathways is a function of dose and the expression level of the target, as well as a function of the kinetics of receptor internalization and intracellular catabolism.Monoclonal antibodies marketed for therapeutic useAntibodyIsotypestructurePrimary indicationAbciximabChimeric mousehuman FabPrevention of cardiac ischemic complicationsAdalimumabHuman lgG1Rheumatoid arthritisAlemtuzumabCDR-grafted rathuman IgG1B-cell chronic lymphocytic leukemiaBasiliximabChimeric mousehuman IgG1Prophylaxis of acute organ rejectionBevacizumabCDR-grafted mousehuman lgG1Colorectal, lung, and breast cancerCertolizumab pegotPEGylated FabCrohns diseaseCetuximabChimeric mousehuman lgG1Head and neck cancer, colorectal cancerDaclizumabCDR-grafted mousehuman lgG1Prophylaxis of acute organ rejectionEculizumabCDR-grafted mousehuman lgG2lgG4Paroxysmal nocturnal hemoglobinuriaEfalizumabCDR-grafted mousehuman lgG1PsoriasisGemtuzumab ozogamicinCDR-grafted mousehuman lgG4Acute myeloid leukemiaIbritumomab tiuxetanMurine lgG1Non-Hodgkins lymphomaInfliximabChimeric mousehuman lgG1Rheumatoid arthritis, Crohns diseaseMuromonab-CD3Murine lgG2aAcute organ rejectionNatalizumabCDR-grafted mousehuman lgG4Multiple sclerosisOmalizumabCDR-grafted mousehuman lgG1AsthmaPativizumabCDR-grafted mousehuman lgG1Prevention of respiratory tract diseasePanitumumabHuman lgG2Colorectal cancerRanibizumabCDR-grafted human IgG1 FabMacular degenerationRituximabChimeric mousehuman IgG1Non-Hodgkins lymphoma, rheumatoid arthritisTositumomabMurine lgG2aNon-Hodgkins lymphomaTrastuzumabCDR-grafted mousehuman lgG1Breast cancerCDR, complementarity determining region: IgG, immunoglobulin G. 